MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
securities in registered...
$4,178,162
Proceeds from sale of
securities in registered...
$2,245,040
Exercise of common stock
warrants
$45,800
Net cash provided by
financing activities
$6,469,002
Net increase
(decrease)
$1,848,922
Canceled cashflow
$4,620,080
General and
administrative costs
$1,144,348
Unrealized gain (loss) on
digital assets
-$182,887
Accounts payable and
accrued expenses
$95,661
Common stock issued for
services
$44,711
Other prepaid
expenses
-$23,814
Research and development
contract liabilities
$77
Net cash used in
investing activities
-$2,637,360
Net cash used in
operating activities
-$1,982,720
Canceled cashflow
$1,491,498
Purchase of digital
assets
$2,637,360
Net loss
-$3,465,626
Prepaid insurance
$8,592
Back
Back
Cash Flow
source: myfinsight.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXTW)